Vafidemstat is under clinical development by Oryzon Genomics and currently in Phase II for Borderline Personality Disorder (BPD). According to GlobalData, Phase II drugs for Borderline Personality Disorder (BPD) does not have sufficient historical data to build an indication benchmark PTSR for Phase II. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the Vafidemstat LoA Report. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Vafidemstat overview
Vafidemstat (ORY-2001) is under development for the treatment of Phelan-McDermid Syndrome, Alzheimer's disease, Huntington’s disease, Parkinson's disease, other dementias, relapsing-remitting multiple sclerosis and secondary progressive multiple sclerosis, aggressiveness (psychosis) associated with psychiatric and neuro-degenerative diseases such as lewy body dementia (DLB), Alzheimer's disease, autism spectrum syndrome (ASD), borderline personality disorder (BPD) and adult attention deficit hyperactivity disorder (ADHD), Kabuki syndrome, Schizophrenia other autoimmune and orphan CNS diseases, pneumonia/acute respiratory distress syndrome in seriously ill COVID-19 patients. The drug candidate is administered orally, formulated as capsule. It targets monoamine oxidase type B (MOA-B) and lysine specific histone demethylase 1A (LSD1). The drug candidate is developed based on the epigenetic platform.
Oryzon Genomics overview
Oryzon Genomics (Oryzon) is a clinical-stage biopharmaceutical company that discovers and develops epigenetic therapies to treat oncology and neurodegenerative diseases. The company provides epigenetics, a regulatory system that controls gene expression without affecting the makeup of the genes themselves and provides regulation of gene transcription that has emerged as a key biological determinant of protein production and cellular differentiation. Oryzon clinical-stage products include ORY-1001, an oncology product for treating acute leukemia disease, ORY-2001 for treating Alzheimer’s disease, Parkinson’s disease and others and ORY-3001 for treating other indications of cancer and ORY-4001 a selective HDAC6 inhibitor. It provides therapeutic programs and collaborative research services. It operates offices in Spain and the US. Oryzon is headquartered in Cornella de Llobregat, Barcelona, Spain.
For a complete picture of Vafidemstat’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
